Suppression of survivin induced by a BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs
Molecular Cancer Therapeutics (2013) - Comments
pubmed: 23536723  doi: 10.1158/1535-7163.mct-12-0550  issn: 1538-8514  issn: 1535-7163 

Stefania Stella, Elena Tirrò, Enrico Conte, Fabio Stagno, Francesco Di Raimondo, Livia Manzella, Paolo Vigneri